Open Access

Genes targeted by the estrogen and progesterone receptors in the human endometrial cell lines HEC1A and RL95-2

Contributed equally
Reproductive Biology and Endocrinology20097:150

https://doi.org/10.1186/1477-7827-7-150

Received: 9 October 2009

Accepted: 24 December 2009

Published: 24 December 2009

Abstract

Background

When the steroid hormones estrogen and progesterone bind to nuclear receptors, they have transcriptional impact on target genes in the human endometrium. These transcriptional changes have a critical function in preparing the endometrium for embryo implantation.

Methods

382 genes were selected, differentially expressed in the receptive endometrium, to study their responsiveness of estrogen and progesterone. The endometrial cell lines HEC1A and RL95-2 were used as experimental models for the non-receptive and receptive endometrium, respectively. Putative targets for activated steroid hormone receptors were investigated by chromatin immunoprecipitation (ChIP) using receptor-specific antibodies. Promoter occupancy of the selected genes by steroid receptors was detected in ChIP-purified DNA by quantitative PCR (qPCR). Expression analysis by reverse transcriptase (RT)-PCR was used to further investigate hormone dependent mRNA expression regulation of a subset of genes.

Results

ChIP-qPCR analysis demonstrated that each steroid hormone receptor had distinct group of target genes in the endometrial cell lines. After estradiol treatment, expression of estrogen receptor target genes predominated in HEC1A cells (n = 137) compared to RL95-2 cells (n = 35). In contrast, expression of progesterone receptor target genes was higher in RL95-2 cells (n = 83) than in HEC1A cells (n = 7) after progesterone treatment. RT-PCR analysis of 20 genes demonstrated transcriptional changes after estradiol or progesterone treatment of the cell lines.

Conclusions

Combined results from ChIP-qPCR and RT-PCR analysis showed different patterns of steroid hormone receptor occupancy at target genes, corresponding to activation or suppression of gene expression after hormone treatment of HEC1A and RL95-2 cell lines.

Background

The human endometrium is a dynamic tissue that undergoes cyclic changes in preparation for endometrial receptivity and embryo implantation. Endometrial development consists of proliferative and secretory phases, and the two major regulators of this process are the ovarian steroid hormones 17β-estradiol (E2) and progesterone (P4). In the proliferative phase, estrogens stimulate the proliferation of the epithelial and stromal components of the endometrium, while in the secretory phase P4 is involved in glandular differentiation and inhibition of E2-mediated cell proliferation [1]. In the absence of implantation, declining levels of P4 and E2 signal the degeneration of the endometrial tissue, which is followed by regeneration during the next cycle.

The biological activities of E2 and P4 are mediated mainly by nuclear receptors (NRs). Binding of a steroid hormone to its cognate receptor results in a conformational change in the NR that allows the ligand-NR complex to bind with high affinity to response elements in DNA and regulate transcription of target genes. Two types of E2 receptors, ERα and ERβ, encoded by separate genes, are found in humans [2, 3]. Although ERα and ERβ are present in all endometrial cell types over the entire menstrual cycle, they are expressed at higher levels during the proliferative phase and show lower activity during the secretory phase because of the suppressive effect of P4 [4].

P4 signalling is also mediated by two receptors, PRA and PRB [5], which are encoded by the same gene but transcribed from different promoters, resulting in a PRB that has an additional 164 amino acids at the N-terminus [6]. PRB is a stronger transcriptional activator in most cell types, while PRA acts often as a dominant negative repressor for PRB activity [7, 8]. PRA and PRB levels are similar during the proliferative phase. In the early secretory phase, PRA is dominant, while higher PRB levels during the mid-secretory phase have been described [9]. The expression of the PR gene in endometrial glands is controlled by E2 and P4, where E2 induces PR synthesis and P4 down-regulates the expression of its own receptor [1].

Implantation of the developing embryo involves a molecular dialogue between the endometrium and blastocyst that involves a number of specific mediators including membrane receptors, components of the extra-cellular matrix, growth factors, cytokines and lipid components of the cell membranes [10]. The endometrium is receptive for embryo attachment only during a restricted period called the "implantation window" (IW). In humans, the IW is limited to days 20-24 of the menstrual cycle and is achieved through the coordinated action of P4 and E2. Thus, an imbalance of steroid hormone levels and their ratios could influence the regulation of target genes, leading to female infertility by disturbing endometrial receptivity during the IW.

Microarray technology has led to genome-wide identification of gene expression pathways involved in implantation events. Based on five transcriptome studies [1115], we selected 382 genes with different expression levels during the IW in human endometrium. The aim of this study was to investigate whether these pre-selected genes could be directly regulated by E2 and P4 through their specific receptors. To achieve the purpose, to study hormone dependent receptivity of the endometrium, we used two human uterine epithelial cell lines as in vitro models.

HEC1A was used as a model of non-receptive endometrium, and RL95-2 was used as a model of receptive endometrium [1619]. The cell lines were chosen based on earlier studies which have demonstrated that RL95-2 cells have stronger adhesiveness for human JAR choriocarcinoma multicellular spheroids compared to HEC1A cells [2022] and are thus considered as a model of the receptive endometrium. Following hormone treatment of the cells, binding of steroid hormone receptors to the promoters of selected genes was investigated by chromatin immunoprecipitation (ChIP) with specific antibodies, and detection of the isolated genomic sequences with quantitative PCR (qPCR). E2- and P4-dependent gene regulation was confirmed for 20 genes by reverse transcriptase (RT)-PCR.

Methods

Endometrial cell culture

HEC1A (#HTB-112, American Type Culture Collection, ATCC, Teddington, UK) cells were grown in McCoy 5A medium (#A1324, AppliChem GmbH, Darmstadt, Germany), while RL95-2 (#CRL-1671, ATCC) cells were maintained in DMEM/F12 (AppliChem GmbH) medium with 10 mM Hepes and 5 μl/ml insulin. Both media were supplemented with 2 g/L sodium bicarbonate (AppliChem GmbH), 10% fetal bovine serum (FBS) (AppliChem GmbH) and 1% penicillin/streptomycin (AppliChem GmbH). Both studied cell lines express E2 and P4 specific nuclear receptors (ERα, ERβ, PRA, PRB) as indicated by the ATCC. For hormonal treatment, E2 (Sigma-Aldrich, Helsinki, Finland) or P4 (4-Pregnene-3,20-dione, Sigma-Aldrich) was added to the culture media to a final concentration of 10-8M as described before [23, 24]. For cultures with hormone supplements, dextran-coated charcoal-treated FBS and media without phenol red were used for 48 h prior to experiments to adapt similar conditions and avoid possible hormone-like (estrogenic) activity of Phenol red. Hormone treatment was 45 min for ChIP experiments and 3 h, 6 h or 12 h for mRNA experiments.

Chromatin immunoprecipitation

Chromatin was immunoprecipitated as previously described [25], using following antibodies: monoclonal mouse anti-human ERα antibody (D-12, sc-8005); polyclonal rabbit anti-human ERβ antibody (H-150, sc-8974); monoclonal mouse anti-human PRAB antibody (AB-52, sc-810) that recognizes both human PRA and PRB receptors (AB-52, sc-810); and monoclonal mouse anti-human PRB antibody (B-30, sc-811) that recognizes only the additional NH2-terminal stretch of PRB receptor (Santa Cruz Biotech, CA, USA). Preliminary experiments determined an optimal formaldehyde cross-linking time of 15 min for both cell lines. Chromatin was fragmented to an average size of 0.5 - 2 kb using a Vibra-Cell ultrasonic processor (Sonics, Newtown, CT USA). Antibody-antigen complexes were precipitated with GammaBind™ plus Sepharose™ (GE Healthcare Life Sciences, Uppsala, Sweden), eluted with hot 0.1% SDS and uncrosslinked overnight at 65°C in the presence of Protein K (Sigma-Aldrich). DNA was purified using a Gel Extraction Kit (Qiagen, Helsinki, Finland). Control experiments used preimmune total IgG (Cell Signalling Technology, Inc, Danvers, MA, USA) to estimate the non-specific binding by unspecific antibodies.

ChIP-qPCR for detection of genomic sequences

Specific genomic regions in the ChIP DNA samples were detected by qPCR. The 382 genomic targets for PCR were selected from previously published endometrial tissue microarray data (See additional file 1) [1115] using two criteria: (i) ≥ 2-fold up- or down-regulated mRNA expression during IW and (ii) evolutionary conservation of human and murine orthologous sequences. Primers were designed to detect and amplify a region from +1000 to -5000 bp from the transcription start site using the Primer3 program [26] detecting NR involvement in formation of the basal transcription complex. All primers were designed to have a melting temperature (Tm) of 60°C. Primer specificity was controlled using the alignment algorithms BLAT/iPCR [27] and BLAST [28] to search the whole human genome. Primers were obtained from MWG Biotech (Edsberg, Germany). PCR was performed using HotStarTaq Master Mix (Qiagen) with 0.05 ng of template DNA and 1.25 pmol of primers for each reaction, according to the manufacturer's instructions.

PCR products were detected by qPCR using 384-well plates and a SYBR green detection method with an ABI HT7900 RT-PCR machine (Applied Biosystems, Foster City, CA, USA). PCR conditions were: HotStarTaq DNA Polymerase activation step for 14.5 min at 95°C, 40 cycles of denaturation for 30 s at 95°C, annealing for 45 s at 58°C and extension for 45 s at 72°C. A dissociation step was added to confirm the purity of PCR products by melting-curve analysis with 5 min ramping from 60°C to 95°C.

RT-PCR

RNA was extracted using an RNeasy Mini Kit (Qiagen). Cells were washed once with phosphate-buffered saline prior to extraction, lysed directly in the tissue culture dish and homogenized by 10 strokes with an insulin syringe. RNA was prepared according to the manufacturer's protocol. Genes (n = 20, ADAMDEC1, CD86, ETV1, FLT1, FOXA2, GRIP1, HES1, HOXA1, IHH, KLK3, MEF2D, MMP7, NCOA1, OTOF, PLXNA2, RELB, SMARCA2, TBX19, TNC, and ZNF54) were chosen for RT-PCR analysis based on positive ChIP experiment results, focusing mostly on transcription factors (See additional file 2). For mRNA analysis, 5 μg of total RNA was subjected to reverse transcription, using SuperScript® III First-Strand Synthesis SuperMix (#18080-400, Invitrogen Life Technologies, Carlsbad, CA, USA), as described by the manufacturer. GAPDH specific primers were used to normalize the cDNA synthesis with forward and reverse primers CTCTCTGCTCCTCCTGTTCGAC and TGAGCGATGTGGCTCGGCT, respectively. cDNA specific primer pairs were designed using Primer3 software and tested for unspecific priming against human genomic and mRNA sequences using iPCR software (MWG Biotech). Primers were designed to generate amplicons of 75-150 bp with a Tm of 60°C. PCR conditions for reverse transcriptase products were as described above with the exception of a 15 s annealing step at 58°C, and a 30 s extension time to account for the shorter PCR products.

RT-PCR data analysis

Quantitative qPCR results were analysed using the publicly available software Miner [29]. Outliers were excluded manually when the mean coefficient of variation (CV) for CT (cycle threshold) for triplicates was >1%. Expression values for all transcripts were normalized to the endogenous control of GAPDH, and ratios relative to non-treated samples were generated. Relative gene expression ratios were calculated according to GED (Gene Expression Difference) by CT protocol [30], using the average efficiency of each gene and the CT of each triplicate. To compare the effects of hormone treatments on HEC1A and RL95-2 cell lines, statistical analysis was performed on log2-transformed values of gene expression ratios using an unpaired Student's t-test at a 95% confidence level.

Annotation of genes

Gene classifications were carried out using the PANTHER (Protein Analysis THrough Evolutionary Relationships), [31] classification system that specifies genes by functions based on published evidence and evolutionary relationships that predict gene function in the absence of direct experimental evidence. Clustering analysis was performed with the Cluster 3.0 program [32], using uncentered correlation and complete centroid linkage. Inverted CT (CTinv) values were used for clustering qPCR data. The baseline was set to 40 and CTinv was calculated as CTinv = 40-Ct. Visualisation of clustering data was done using Java TreeView software.

Gene annotation, sequence information, gene descriptions and accession numbers (IDs) were downloaded from BioMart [33] NCBI [34] and UCSC genome browser [35] databases. All datasets were imported and kept in a database supported by MySQL database management software [36].

Results

E2- and P4-receptor target genes in HEC1A and RL95-2 cells

Two endometrial cell lines, HEC1A and RL95-2, were used to investigate the steroid hormone-dependent binding of NRs to the promoters of 382 IW-specific genes (See additional file 1). Although the native receptive endometrium is under the combined influence of both E2 and P4, we performed hormonal treatments separately to reveal E2 or P4 dependent action through their specific nuclear receptors. Cells were treated with either E2 or P4 followed by ChIP using antibodies against the steroid hormone receptors: ERα, ERβ, PRB, or PRAB (which recognizes both PRA and PRB receptors). Quantitative qPCR with specific primers was used to detect NR-binding to the promoter region of the selected genes. HEC1A cells were treated with E2 to simulate the non-receptive-like endometrium and with P4 for comparing P4 effects on the two endometrial cell lines. Out of 382 investigated genes, 137 were ER targets: 101 were bound by ERα, 96 were bound by ERβ, and 60 were targets of both receptors (Figure 1A). When the targets common to both ERs (n = 56) and the targets shared by ERs and PRs (n = 7) were excluded, 40 genes were found to be exclusively regulated by ERα and 34 genes by ERβ (Table 1).
Table 1

List of unique target genes for ERα and ERβ in HEC1A cell line after E2 treatment

Gene symbol*

Gene name

  

Unique targets for ERα

Unique targets for ERβ

ABCB10

ATP-binding cassette, subfamily B, member 10

AQP3

Aquaporin 3

ADCYAP1

Adenylate cyclase-activating polypeptide 1

B3GAT3

Beta-1,3-glucuronyltransferase 3

AGL

Amylo-1,6-glucosidase, 4-alpha- glucanotransferase

BMP10

Bone morphogenetic protein 10

APRT

Adenine phosphoribosyltransferase

CLU

Clusterin

ARID5B

AT-rich interaction domain-containing protein 5B

COG5

Component of oligomeric golgi complex 5

C3orf1

Chromosome 3 open reading frame 1

CRSP9

Mediator complex subunit 7

CCL11

Chemokine, CC motif, ligand 11

DMBT1

Deleted in malignant brain tumors 1

CCL7

Chemokine, CC motif, ligand 7

DNAH9

Dynein, axonemal, heavy chain 9

CCT6B

Chaperonin-containing T-complex polypeptide 1, subunit 6B

FECH

Protoporphyria, erythropoietic

CD86

Cd86 antigen

FEN1

FLAP structure-specific endonuclease 1

CEACAM3

Carcinoembryonic antigen-related cell adhesion molecule 3

FYB

FYN-binding protein

CLDN4

Claudin 4

GBAS

Glioblastoma amplified sequence

ECM1

Extracellular matrix protein 1

GPX3

Glutathione peroxidase 3

EDN3

Endothelin 3

GRIP1

Glutamate receptor-interacting protein 1

FBLN2

Fibulin 2

HBB

Hemoglobin--beta locus

FOSL1

FOS-like antigen 1

KIAA0427

KIAA0427

GRIK1

Glutamate receptor, ionotropic, kainate 1

LGTN

Ligatin

GSN

Gelsolin

MEF2D

Myocyte enhancer factor 2D

HOXA1

Homeobox A1

NINJ1

Nerve injury-induced protein 1

ITGB7

Integrin, beta-7

PDGFA

Platelet-derived growth factor, alpha polypeptide

ITPA

Inosine triphosphatase

PENK

Proenkephalin

LGALS8

Lectin, galactoside-binding, soluble, 8

PLXNB3

Plexin B3

MB

Myoglobin

PRODH

Proline dehydrogenase

NEK6

Never in mitosis gene a-related kinase 6

SC65

Synaptonemal complex protein SC65

NID2

Nidogen 2

SERPIND1

Heparin cofactor II

ODF2

Outer dense fiber of sperm tails 2

SLC16A4

Solute carrier family 16 (monocarboxylic acid transporter), member 4

POFUT1

Protein o-fucosyltransferase 1

TDG

Thymine-DNA glycosylase

PWP1

PWP1 homolog (S. Cerevisiae)

TFDP1

Transcription factor DP1

RELB

v-rel avian reticuloendotheliosis viral oncogene homolog b

TGM2

Transglutaminase 2

SEC61B

SEC61 complex, beta subunit

TNC

Tenascin C

SFRS16

Splicing factor, arginine/serine- rich 16

TNFRSF10C

Tumor necrosis factor receptor superfamily, member 10c

SGCB

Sarcoglycan, beta

TP63

Tumor protein p63

SPARC

Secreted protein, acidic, cysteine-rich

TRIP10

Thyroid hormone receptor interactor 10

SPATA2

Spermatogenesis-associated protein 2

WFDC2

WAP four-disulfide core domain 2

SSFA2

Sperm-specific antigen 2

  

TFAP2C

Transcription factor AP2-gamma

  

TRH

Thyrotropin-releasing hormone deficiency

  

TRIM16

Tripartite motif-containing protein 16

  

WNT5A

Wingless-type MMTV integration

site family,

member 5A

  

XCL2

Chemokine, C motif, ligand 2

  

(*) Official gene symbol by HUGO Gene Nomenclature Committee (HGNC).

Figure 1

Cluster analysis of ERα, ERβ, PRAB, PRB target genes in HEC1A and RL95-2 cells after E2 or P4 treatment. Target genes revealed from ChIP-qPCR experiment were clustered with Cluster 3.0 program and visualized using Java TreeView software. A. HEC1A cell line. E2+ERα: 101 ERα target genes after E2 treatment; E2+ERβ: 96 ERβ target genes after E2 treatment; P4+PRAB: 7 PRAB target genes after P4 treatment; and P4+PRB: 2 PRB target genes after P4 treatment. B. RL95-2 cell line. E2+ERα: 17 ERα target genes after E2 treatment; E2+ERβ: 24. ERβ target genes after E2 treatment; P4+PRAB: 52 PRAB target genes after P4 treatment; and P4+PRB: 40 PRB target genes after P4 treatment.

The amino acid sequence of the progesterone receptor PRA is contained within the sequence of PRB, so producing antibodies specific to PRA is not feasible. Therefore, PRA target genes were found by subtracting anti-PRB targets from the common pool of all PRAB-targets as PRB and PRAB overlapping target genes were considered to be PRB-specific. Seven target genes for P4-mediated action in HEC1A cells were identified, 5 for PRA and 2 for PRB (Figure 1A). All PR targets overlapped with ER targets and thus they were not considered to be unique targets for P4 action in HEC1A cells (Table 2).
Table 2

List of PRA and PRB target genes in HEC1A cell line after P4 treatment

Gene symbol*

Gene name

Targets for PRA

 

CD28

CD28 molecule

COL5A2

Collagen, type V, alpha-2

ETS2

V-Ets avian erythroblastosis virus

e26 oncogene homolog 2

MYST4

Histone acetyltransferase MYST4

OTOF

Otoferlin

Targets for PRB

 

TCF4

Transcription factor 4

ZNF167

Zinc finger protein 167

(*) Official gene symbol by HUGO Gene Nomenclature Committee (HGNC).

The RL95-2 cell line was used as a model for the receptive endometrium with E2 and P4 treatments performed separately. ChIP-qPCR analysis revealed four distinct groups of target genes for each steroid hormone receptor (ERα, ERβ, PRA, and PRB) in RL95-2 cells (Figure 1B). After P4 treatment, anti-PR antibodies recognized chromatin from 83 out of the 382 potential target genes; anti PRB for 40 and anti-PRAB for 52, including overlapping targets for two antibodies. After removing common targets between PRs and ERs and subtracting anti-PRB targets from the common pool of all PRAB-targets, 37 genes were considered to be unique targets for PRA and 8 for PRB (Table 3). Although PRAB antibody should detect both PRA and PRB receptor subtypes, 31 genes were targeted solely by PRB and not identified by PRAB antibody. Twenty-five of them were found to be PRB specific, while six were additionally co-regulated by at least one of the ERs. These 25 unique PRB targets were also regarded as PRB-specific, thus resulting in 33 unique PRB target genes (Table 3). E2 treatment of RL95-2 cells resulted in 35 genes bound by ERs, where in total 17 loci were immunoprecipitated by ERα and 24 by ERβ antibody (Figure 1B), including overlapping targets for two antibodies. After deducted common targets, we discovered nine unique target genes for ERα, eight for ERβ (Table 4), and five common targets for both ERs (data not shown).
Table 3

List of unique target genes for PRA and PRB in RL95-2 cell line after P4 treatment

Gene symbol*

Gene name

 

Unique targets for PRA

Unique targets for PRB

APRT

Adenine phosphoribosyltransferase

ARID5B

AT rich interactive domain 5B (MRF1-like)

BNIP1

Bcl2/adenovirus E1B 19-kD protein-interacting protein 1

ARL1

ADP-ribosylation factor-like 1

CCT6B

Chaperonin-containing T-complex polypeptide 1, subunit 6B

BRCA2

Breast cancer 2

CLDN4

Claudin 4

C2orf3

Chromosome 2 open reading frame 3

COL4A6

Collagen, type IV, alpha-6

CORT

Cortistatin

DNAJB1

DNAJ/HSP40 homolog, subfamily b, member 1

CROT

Carnitine O-octanoyltransferase

ECM1

Extracellular matrix protein 1

EIF3I

Eukaryotic translation initiation factor 3, subunit I

EXT1

Exostosin 1

ETV1

ETS variant gene 1

EXTL2

Exostosin-like 2

FGF12

Fibroblast growth factor 12

FGF9

Fibroblast growth factor 9

GADD45A

Growth arrest- and DNA damage-inducible gene GADD45, alpha

FLT1

Fms-related tyrosine kinase 1

GATA2

GATA-binding protein 2

GPLD1

Phospholipase D1, glycosylphosphatidylinositol-specific

GTF2F2

General transcription factor IIf, polypeptide 2, 30-kD

IFNAR2

Interferon, alpha, beta, and omega, receptor 2

HES1

Hairy and enhancer of split 1 homolog

ITGA10

Integrin, alpha-10

IHH

Indian hedgehog

ITGA2

Integrin, alpha-2

KLK3

Kallikrein-related peptidase 3

ITGB7

Integrin, beta-7

MEF2D

Myocyte enhancer factor 2D

KIAA0427

KIAA0427

NCR3

Natural cytotoxicity triggering receptor 3

LAMB1

Laminin, beta-1

NF1

Neurofibromatosis, type I

MAOA

Monoamine oxidase A

NFIX

Nuclear factor I/X (CCAAT-binding transcription factor)

MB

Myoglobin

NUP98

Nucleoporin, 98-kD

MYST4

Histone acetyltransferase MYST4

POSTN

Periostin

NCOA1

Nuclear receptor coactivator 1

PWP1

PWP1 homolog (S. Cerevisiae)

NCOR2

Nuclear receptor corepressor 2

RAD54L

Rad54, s. Cerevisiae, homolog-like

NUP155

Nucleoporin, 155-kD

RNF126

Ring finger protein 126

PDGFA

Platelet-derived growth factor, alpha polypeptide

SEMA3F

Semaphorin 3F

SLC29A2

Solute carrier family 29 (nucleoside transporter), member 2

SNTG1

Syntrophin, gamma-1

SOX4

SRY-box 4

SPATA2

Spermatogenesis-associated protein 2

TGFA

Transforming growth factor, alpha

SPDEF

SAM pointed domain containing ets transcription factor

TIAL1

Tia1 cytotoxic granule-associated rna-binding protein-like 1

STC1

Stanniocalcin 1

TNC

Tenascin C

STIM1

Stromal interaction molecule 1

TRIP10

Thyroid hormone receptor interactor 10

TDRKH

Tudor and KH domains-containing protein

TRMT11

tRNA methyltransferase 11 homolog (S. Cerevisiae)

TLX2

T-cell leukemia, homeobox 2

UBE3C

Ubiquitin protein ligase E3C

UMOD

Uromodulin

UBTF

Upstream binding transcription factor (RNA polymerase I)

  

VEGFA

Vascular endothelial growth factor A

  

XCL2

Chemokine, C motif, ligand 2

  

ZNF549

Zinc finger protein 549

  

(*) Official gene symbol by HUGO Gene Nomenclature Committee (HGNC).

Table 4

List of unique target genes for ERα and ERβ in RL95-2 cell line after E2 treatment

Gene symbol*

Gene name

 

Unique targets for ERα

Unique targets for ERβ

ANXA2

Annexin A2

ETS2

v-ets avian erythroblastosis virus e26 oncogene homolog 2

CHRNB2

Cholinergic receptor, neuronal nicotinic, beta polypeptide 2

FOXA2

Forkhead box A2

COL3A1

Collagen, type III, alpha-1

MMP26

Matrix metalloproteinase 26

GSN

Gelsolin

NINJ1

Nerve injury-induced protein 1

RPS6KB2

Ribosomal protein S6 kinase, 70-kD, 2

SERPIND1

Heparin cofactor II

SECTM1

Secreted and transmembrane 1

SFRS16

Splicing factor, arginine/serine-rich 16

SMARCA2

SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 2

TBX19

T-box 19

SC65

Synaptonemal complex protein SC65

VDAC1

Voltage-dependent anion channel 1

VLDLR

Very low density lipoprotein receptor

  

(*) Official gene symbol by HUGO Gene Nomenclature Committee (HGNC).

The total number of genes targeted after E2 treatment of HEC1A and RL95-2 cells is shown in Figure 1. Approximately four times as many genes were bound by ERs in HEC1A cells than in RL95-2 cells, which had 137 and 35 target genes, respectively. These results confirmed that HEC1A is a better model of the non-receptive endometrium with E2 exerting its primary role in tissue proliferation. In contrast, P4 treatment resulted in 10 times more PR targets in RL95-2 cells (n = 83) than in HEC1A cells (n = 7), supporting the view of RL95-2 cell line as a model for the receptive endometrium with P4 preparing the endometrium for embryo nidation.

E2- and P4-mediated mRNA expression in HEC1A and RL95-2 cell lines

To elucidate the biological significance of the molecular interactions seen by ChIP, we complemented the initial results with mRNA expression studies for 20 genes (See additional file 2). All selected genes were detected as NR targets by ChIP-qPCR and half (n = 10) of them were classified as transcription factors. The other criteria after transcription factors was to find genes which has not been described as an ER or PR targets before.

HEC1A and RL95-2 cells were treated with E2 or P4 for 3, 6, or 12 h. At least 2-fold up- or down-regulation of mRNA expression levels were detected for 12 genes (CD86, FOXA2, IHH, MEF2D, MMP7, NCOA1, OTOF, PLXNA2, RELB, SMARCA2, TNC, and ZNF549) out of 20 genes studied (Table 5). Although, the activities of transcription factor coding genes GRIP1 and TBX19 changed significantly during the hormonal treatments, these alterations remained below the 2-fold threshold. cDNA amplification was not observed for 6 genes ADAMDEC1, ETV1, FLT1, HES1, HOXA1 and KLK3 in either cell line regardless of hormonal treatment (data not shown). Surprisingly, the observed changes in E2- or P4-dependent mRNA expression occasionally conflicted with the ChIP-qPCR results. For example, although the secreted growth factor Indian hedgehog (IHH) and otoferlin (OTOF) were detected as E2-ER targets in HEC1A cells, E2-induced mRNA expression was observed in RL95-2 cells but not in HEC1A cells.
Table 5

Genes > 2 fold up- or down-regulated after hormone treatment in HEC1A and/or RL95-2 cell line

Up-regulation > 2 fold

 

ChIP target post E2 treatment

 

ChIP target post P4 treatment

HEC1A

Molecular function*

E2

 

P4

 

MEF2D

Other transcription factor; Nucleic acid binding

6 h

HEC1A ERβ

3 h

RL95-2 PRB

RL95-2

 

E2

 

P4

 

CD86

Immunoglobulin receptor family member; Membrane-bound signaling molecule; Defense/immunity protein

3 h

HEC1A ERα

NS

ND

MEF2D

Other transcription factor; Nucleic acid binding

3 h

HEC1A ERβ

3 h

RL95-2 PRB

OTOF

Otoferlin

12 h

HEC1A ERα and ERβ

3 h

HEC1A PRA

PLXNA2

Tyrosine protein kinase receptor;Protein kinase

3 h

RL95-2 ERβ

3 h

RL95-2 PRA

RELB

Other transcription factor

3 h

HEC1A ERα

NS

ND

SMARCA2

DNA helicase

3 h

RL95-2 ERα

3 h

ND

TNC

Cell adhesion molecule; Extracellular matrix glycoprotein

3 h

HEC1A ERβ

3 h

RL95-2 PRA

Down-regulation > 2 fold

    

HEC1A

Molecular function*

E2

 

P4

 

CD86

Immunoglobulin receptor family member; Membrane-bound signaling molecule; Defense/immunity protein

6 h

HEC1A ERα

NS

ND

FOXA2

Other transcription factor; Nucleic acid binding

3 h

RL95-2 ERβ

12 h

ND

MMP7

Metalloprotease; Other extracellular matrix

12 h

HEC1A ERα and ERβ

12 h

ND

NCOA1

Transcription factor; Acetyltransferα se

3 h

ND

6 h

RL95-2 PRA

RELB

Other transcription factor

3 h

HEC1A ERα

6 h

ND

TNC

Cell adhesion molecule; Extracellular matrix glycoprotein

3 h

HEC1A ERβ

6 h

RL95-2 PRA

ZNF549

KRAB box transcription factor

 

HEC1A ERα and ERβ

6 h

RL95-2 PRA

RL95-2

 

E2

 

P4

 

CD86

Immunoglobulin receptor family member; Membrane-bound signaling molecule; Defense/immunity protein

12 h

HEC1A ERα

NS

ND

IHH

Other signaling molecule; Protease

12 h

HEC1A ERα/ERβ

6 h

RL95-2 PRB

(*) Molecular functions were obtained from PANTHER. In bold are genes with cell line-specific expression. NS: not significant gene expression, ND: not detected. Official gene symbols according to HUGO Gene Nomenclature Committee (HGNC).

From the selected 20 genes five genes showed significant cell line-specific mRNA expression either in HEC1A or RL95-2 cell line (Table 5, in bold). IHH expression was detected in RL95-2 cell line-specific manner until 6 h after E2 treatment or 3 h after P4 treatment, but was down-regulated after longer hormonal exposure. In addition to IHH, the expression of three other genes: plexin A2 (PLXNA2), OTOF and a SWI/SNF related family member (SMARCA2) were induced by E2 or P4 in the RL95-2 cell line. In HEC1A cells, on the contrary, the expression of matrix metalloprotease 7 (MMP7) was detected in non-treated HEC1A cells and was gradually down-regulated after treatments by both hormones.

Analysis of gene expression in HEC1A and RL95-2 cell lines showed almost opposite responses to E2 and P4. A significant difference (p < 0.05) in transcript levels was observed between the two cell lines in the expression of nine genes after E2 treatment (Figure 2). Furthermore, CD86, FOXA2, GRIP1, NCOA1, RELB, TBX19, TNC, and ZNF549 genes showed opposite regulation in the two cell lines, with mRNA levels up-regulated in RL95-2 cells but down-regulated in HEC1A cells after E2 treatment when compared to non-treated samples (Figure 2). The expression of MEF2D was also significantly different between the cell lines, but unlike the other genes, it was up-regulated by E2 in both cell lines. P4 similarly exerted opposite effects on gene expression in the two endometrial cell lines as mRNA levels of the three transcription factor genes FOXA2, NCOA1, TBX19, and extracellular matrix tenascin-C (TNC) gene were significantly (p < 0.05, Figure 3) up-regulated in RL95-2 cells and down-regulated in HEC1A cells post P4 treatment.
Figure 2

E2 mediated time-dependant gene expression in RL95-2 (blue) and HEC1A (red) cell lines compared to non-treated samples. Expression profiles of CD86, FOXA2, GRIP1, NCOA1, RELB, TBX19, TNC, ZNF549, and MEF2D genes had significant difference (p < 0.05, two-tailed, unpaired Student's t-test with 95% confidence of log2-transformed expression ratios relative to baseline expression) in mRNA expression ratios (*) between RL95-2 and HEC1A cells after E2 treatment. E2 exposure predominantly induced mRNA level of gene expression in RL95-2 cells but down-regulated in HEC1A cells (except for MEF2D gene).

Figure 3

P4 mediated time-dependant gene expression in RL95-2 (blue) and HEC1A (red) cell lines compared to non-treated samples. Expression profiles of FOXA2, NCOA1, TBX19 and TNC genes had significant difference (p < 0.05, two-tailed, unpaired Student's t-test with 95% confidence of log2-transformed expression ratios relative to baseline expression) in mRNA expression ratios (*) between RL95-2 and HEC1A cells after P4 treatment. P4 mostly induced mRNA level in RL95-2 cells but down-regulated in HEC1A cells.

Discussion

The exact molecular characteristics of the embryo impantation are still not completely characterised because of the complexity of using human embryos and endometrial tissue in reseach, therefore other means must be elucidated for research of receptivity of the endometrium. Used RL95-2 and HEC1A cell lines are both described as endometrial epithelial cell lines derived from adenocarcinoma cells. Our interest to investigate the suitability of selected cell lines as an in vitro models of non-receptive and receptive endometrium was based on several studies published recently [21, 22, 37, 38]. RL95-2 cell line has been characterized as a model of receptive endometrium by its ability to mimic relevant properties of the adhesion competent endometrial lining compared to HEC1A [21, 22].

The steroid hormones E2 and P4 bind to NRs to play a key role in preparing the endometrium for implantation of an embryo. NRs regulate transcription by binding to the proximal or distal regulatory regions of specific genes. Transcriptional changes regulated by NRs have been suggested to involve chromosomal looping or PolII tracking that allows enhancers to interact with the transcription complex at the promoter [39]. In this study, we used ChIP-qPCR method to investigate whether genes previously identified as IW-specific become direct targets of NRs after hormonal treatment of endometrial cells.

Combining new technologies based on microarrays and high-throughput sequencing with the today's knowledge of entire human genome allows defining of all in vivo targets for transcription machinery in a single experiment [23, 24]. Since NR activity is often tissue specific, we used primers specifically designed to detect the promoter regions of 382 genes known to exhibit differential expression in the human receptive endometrium. Our specific aim was to investigate whether the steroid hormone actions in endometrial cell lines HEC1A and RL95-2 support their use as non-receptive and receptive endometrial models, respectively.

In non-receptive endometrium, the primary role of E2 is in tissue regeneration and proliferation. Analysis of the number of ER target genes identified by ChIP-qPCR after E2 treatment under our experimental conditions, revealed almost 4-fold difference between HEC1A (n = 137) and RL95-2 (n = 35) cells. This finding supports the idea of HEC1A as a good model for non-receptive endometrium being predominantly governed by E2 control. In addition to unique targets of ERα and ERβ, we identified a subset of 60 genes in HEC1A cells and 5 genes in RL95-2 cells that were common for both ERs.

Previous in vitro studies have demonstrated that both homodimers ERα/ERα or ERβ/ERβ and heterodimers ERα/ERβ can be formed when both ER subtypes are expressed in the same cell [40]. Moreover, it has been shown that in the absence of ERα, ERβ can either inhibit ERα-mediated gene transcription or partly replace ERα as a transcription factor [41]. Thus, the common ERα and ERβ targets identified in this study could represent genes either activated by heterodimeric complexes or could reflect competitive binding of the two separate E2 receptors to the same regulatory element.

In receptive endometrium, the primary role of P4 is the preparation of the endometrium for embryo implantation. From our set of 382 genes, 83 were bound by PRs in RL95-2 cells, which was ten times more than in the HEC1A cell line (n = 7). Harduf and colleagues have demonstrated that there is a higher PRA/PRB ratio in RL95-2 cells compared to HEC1A cells indicating the possible important role of PRA during implantation window [22]. Even the both cell lines express E2 and P4 specific receptors (ATCC) the lack of specific antibody against PRA has made it difficult to compare the exact ratio levels of two PRs.

To investigate transcriptional changes that occur after NR binds to its promoter region, we assessed the expression of 20 selected genes. RT-PCR analysis showed that 12 out of selected 20 IW-specific genes had at least 2-fold up- or down-regulation in mRNA expression level after hormonal treatment. Five genes were expressed in cell line-specific manner as the expression of IHH, PLXNA2, OTOF, and SMARCA2 was only observed in RL95-2 cells, while MMP7 activity was detected exclusively in HEC1A cells.

We included IHH as a classical example of steroid hormone-dependent gene regulation during IW. Previous in vivo and in vitro studies revealed that the expression of IHH in the murine uterus is solely P4 dependent and essential for embryo implantation [4244]. Our results showed that IHH was the target gene for PRB after P4 treatment in RL95-2 cells. Indeed, RT-PCR analysis confirmed IHH expression only in RL95-2 cells. Interestingly, the mRNA levels of IHH in RL95-2 cells were suppressed after the use of either E2 or P4 hormones (Table 5), differentially from murine uterus where IHH expression depends only on P4 [4244]. Yet, the recent work has indicated that the stromal not epithelial PR is critical for P4-mediated induction of IHH expression in the mouse uterus [45]. Since the HEC1A and RL95-2 cell lines represent the epithelial cells of the endometrium, IHH expression in this endometrial compartment may be regulated by other hormonal mechanisms from internal tissue layers. Species difference between the estrous cycle of mice and the menstrual cycle in women is an additional factor to account for this discrepancy.

Our gene expression analysis focused mainly on transcription factors. Since the development and regeneration of endometrial tissue is largely governed by E2 and P4, a transcriptional regulatory feedback system is needed to mediate these dynamic and complex changes. The majority of E2-regulated genes are thought to be up-regulated after short (1-8 h) hormonal treatment, while most of the hormone-responsive genes are down-regulated after longer (12-48 h) treatment [39]. We examined the changes in mRNA expression following 3-12 h of hormonal exposure in order to investigate the rapid transcriptional changes caused by steroid hormones. We found that the increase of mRNA level in selected genes mainly occurred after short-term (3-6 h) treatment, while the majority of suppressive effects become visible after 6-12 h of treatment (Table 5, Figures 2 and 3).

Interestingly, when hormone responsiveness in two endometrial cell lines was compared, we found that hormonal treatments had almost opposite effects on gene expression. Treatments with E2 or P4 resulted in significant up- and down-regulation of genes in RL95-2 and HEC1A cells, respectively. Genes for the transcription factors FOXA2, NCOA1, TBX19, and the extracellular matrix glycoprotein TNC had markedly different and opposite mRNA expression levels after E2 or P4 treatment in both of the cell lines investigated. All four genes were either down-regulated by both hormones in HEC1A or up-regulated in RL95-2 cells (Figures 2 and 3). In addition to already mentioned genes, E2 had also an inverse effect on CD86, GRIP1, RELB, and ZNF549 mRNA expression in the two endometrial cell lines, up-regulated in RL95-2 and down-regulated in HEC1A cells.

Some of the genes (ADAMDEC1, ETV1, FLT1, HES1, HOXA1 and KLK3) did not show any evidence of gene activity in both cell lines in spite of hormonal treatment. As all genes were selected from previous expression studies with human endometrium tissue samples the revealed effect could be cell line specific. In addition, we have to take into account that NR binding alone is not always sufficient to induce gene expression changes. The various combinations of transcription co-activators or -repressors are also required for proper gene activity, depending on the specific cell and tissue background [4648]. In studying steroid hormone signalling, the non-genomic actions of steroid hormones in cross-talk between the growth factor receptors and cytoplasmic response must also be considered along with the direct transcriptional effects mediated by NRs [49, 50].

In present study we gained new information about the specific action of E2 and P4 during different stages of human endometrial development using a combination of ChIP-qPCR and RT-PCR. HEC1A and RL95-2 cell lines showed different sets of ER and PR target genes in response to hormonal stimuli as more target genes were detected for ERs in HEC1A cells than for PRs in RL95-2 cells. We also observed that hormone treatment had different impacts on gene expression levels in the two cell lines. The ChIP and RT-PCR results show that E2 and P4 actions in the human endometrium are more complex than the classic steroid hormone effects mediated through NRs.

Conclusions

The presented data demonstrates that the endometrial cell lines HEC1A and RL95-2 are suitable in vitro models for evaluating the effects of steroid hormones in non-receptive and receptive endometrium, respectively. This study deepens our understanding on the hormone responsive gene regulation during the cyclic changes in the human endometrium. However, further studies are needed to elucidate the complex mechanism by which endometrium acquires its receptivity.

Notes

Declarations

Acknowledgements

This work has been supported by the Tallinn University of Technology (Targeted project no. B611), Estonian Ministry of Education and Science (Targeted project no. SF0180044s09) and Enterprise Estonia (Grant no. EU30200).

Authors’ Affiliations

(1)
Centre for Biology of Integrated Systems, Tallinn University of Technology
(2)
Nova Vita Clinic, Centre for infertility treatment and medical genetics
(3)
Department of Obstetrics and Gynecology, University of Tartu
(4)
Department of Biotechnology, Institute of Molecular and Cell Biology, University of Tartu
(5)
Competence Centre on Reproductive Medicine and Biology

References

  1. Graham RA, Seif MW, Aplin JD, Li TC, Cooke ID, Rogers AW, Dockery P: An endometrial factor in unexplained infertility. Bmj. 1990, 300 (6737): 1428-1431. 10.1136/bmj.300.6737.1428.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson JA: Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 1997, 82 (12): 4258-4265. 10.1210/jc.82.12.4258.PubMedGoogle Scholar
  3. Kuiper GG, Gustafsson JA: The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett. 1997, 410 (1): 87-90. 10.1016/S0014-5793(97)00413-4.View ArticlePubMedGoogle Scholar
  4. Matsuzaki S, Fukaya T, Suzuki T, Murakami T, Sasano H, Yajima A: Oestrogen receptor alpha and beta mRNA expression in human endometrium throughout the menstrual cycle. Mol Hum Reprod. 1999, 5 (6): 559-564. 10.1093/molehr/5.6.559.View ArticlePubMedGoogle Scholar
  5. Wen DX, Xu YF, Mais DE, Goldman ME, McDonnell DP: The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol. 1994, 14 (12): 8356-8364.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Kastner P, Bocquel MT, Turcotte B, Garnier JM, Horwitz KB, Chambon P, Gronemeyer H: Transient expression of human and chicken progesterone receptors does not support alternative translational initiation from a single mRNA as the mechanism generating two receptor isoforms. J Biol Chem. 1990, 265 (21): 12163-12167.PubMedGoogle Scholar
  7. Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB: Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol. 1993, 7 (10): 1256-1265. 10.1210/me.7.10.1256.PubMedGoogle Scholar
  8. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP: Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol. 1993, 7 (10): 1244-1255. 10.1210/me.7.10.1244.PubMedGoogle Scholar
  9. Arnett-Mansfield RL, DeFazio A, Mote PA, Clarke CL: Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium. J Clin Endocrinol Metab. 2004, 89 (3): 1429-1442. 10.1210/jc.2003-031111.View ArticlePubMedGoogle Scholar
  10. Dimitriadis E, White CA, Jones RL, Salamonsen LA: Cytokines, chemokines and growth factors in endometrium related to implantation. Hum Reprod Update. 2005, 11 (6): 613-630. 10.1093/humupd/dmi023.View ArticlePubMedGoogle Scholar
  11. Kao LC, Tulac S, Lobo S, Imani B, Yang JP, Germeyer A, Osteen K, Taylor RN, Lessey BA, Giudice LC: Global gene profiling in human endometrium during the window of implantation. Endocrinology. 2002, 143 (6): 2119-2138. 10.1210/en.143.6.2119.View ArticlePubMedGoogle Scholar
  12. Krikun G, Schatz F, Taylor R, Critchley HO, Rogers PA, Huang J, Lockwood CJ: Endometrial endothelial cell steroid receptor expression and steroid effects on gene expression. J Clin Endocrinol Metab. 2005, 90 (3): 1812-1818. 10.1210/jc.2004-1814.View ArticlePubMedGoogle Scholar
  13. Mirkin S, Arslan M, Churikov D, Corica A, Diaz JI, Williams S, Bocca S, Oehninger S: In search of candidate genes critically expressed in the human endometrium during the window of implantation. Hum Reprod. 2005, 20 (8): 2104-2117. 10.1093/humrep/dei051.View ArticlePubMedGoogle Scholar
  14. Punyadeera C, Dassen H, Klomp J, Dunselman G, Kamps R, Dijcks F, Ederveen A, de Goeij A, Groothuis P: Oestrogen-modulated gene expression in the human endometrium. Cell Mol Life Sci. 2005, 62 (2): 239-250. 10.1007/s00018-004-4435-y.View ArticlePubMedGoogle Scholar
  15. Carson : Changes in gene expression during the early to mid-luteal (receptive phase) transition in human endometrium detected by high-density microarray screening. Molecular Human Reproduction. 2002, 8 (No 9): 871-879. 10.1093/molehr/8.9.871.View ArticlePubMedGoogle Scholar
  16. Kuramoto H, Tamura S, Notake Y: Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol. 1972, 114 (8): 1012-1019.PubMedGoogle Scholar
  17. Way DL, Grosso DS, Davis JR, Surwit EA, Christian CD: Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture. In Vitro. 1983, 19 (3 Pt 1): 147-158. 10.1007/BF02618053.View ArticlePubMedGoogle Scholar
  18. John NJ, Linke M, Denker HW: Retinoic acid decreases attachment of JAR choriocarcinoma spheroids to a human endometrial cell monolayer in vitro. Placenta. 1993, 14 (1): 13-24. 10.1016/S0143-4004(05)80245-0.View ArticlePubMedGoogle Scholar
  19. Rohde LH, Carson DD: Heparin-like glycosaminoglycans participate in binding of a human trophoblastic cell line (JAR) to a human uterine epithelial cell line (RL95). J Cell Physiol. 1993, 155 (1): 185-196. 10.1002/jcp.1041550124.View ArticlePubMedGoogle Scholar
  20. Thie M, Fuchs P, Butz S, Sieckmann F, Hoschutzky H, Kemler R, Denker HW: Adhesiveness of the apical surface of uterine epithelial cells: the role of junctional complex integrity. Eur J Cell Biol. 1996, 70 (3): 221-232.PubMedGoogle Scholar
  21. Harduf H, Goldman S, Shalev E: Human uterine epithelial RL95-2 and HEC-1A cell-line adhesiveness: the role of plexin B1. Fertil Steril. 2007, 87 (6): 1419-1427. 10.1016/j.fertnstert.2006.11.141.View ArticlePubMedGoogle Scholar
  22. Harduf H, Goldman S, Shalev E: Progesterone receptor A and c-Met mediates spheroids-endometrium attachment. Reprod Biol Endocrinol. 2009, 7: 14-10.1186/1477-7827-7-14.PubMed CentralView ArticlePubMedGoogle Scholar
  23. Carroll JS, Brown M: Estrogen receptor target gene: an evolving concept. Mol Endocrinol. 2006, 20 (8): 1707-1714. 10.1210/me.2005-0334.View ArticlePubMedGoogle Scholar
  24. Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP, Lipovich L, Barnett DH, Stossi F, et al: Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet. 2007, 3 (6): e87-10.1371/journal.pgen.0030087.PubMed CentralView ArticlePubMedGoogle Scholar
  25. Weinmann AS: Novel ChIP-based strategies to uncover transcription factor target genes in the immune system. Nat Rev Immunol. 2004, 4 (5): 381-386. 10.1038/nri1353.View ArticlePubMedGoogle Scholar
  26. Primer3 programm. [http://frodo.wi.mit.edu/primer3/]
  27. Kent WJ: BLAT--the BLAST-like alignment tool. Genome Res. 2002, 12 (4): 656-664.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25 (17): 3389-3402. 10.1093/nar/25.17.3389.PubMed CentralView ArticlePubMedGoogle Scholar
  29. Miner software. [http://www.miner.ewindup.info]
  30. Schefe JH, Lehmann KE, Buschmann IR, Unger T, Funke-Kaiser H: Quantitative real-time RT-PCR data analysis: current concepts and the novel "gene expression's CT difference" formula. J Mol Med. 2006, 84 (11): 901-910. 10.1007/s00109-006-0097-6.View ArticlePubMedGoogle Scholar
  31. Protein Analysis THrough Evolutionary Relationships. [http://www.pantherdb.org]
  32. Cluster 3.0 program. [http://bonsai.ims.u-tokyo.ac.jp/~mdehoon/software/cluster/software.htm]
  33. BioMart. [http://www.biomart.org]
  34. National Center for Biotechnology Information. [http://www.ncbi.nlm.nih.gov]
  35. UCSC genome browser. [http://genome.ucsc.edu]
  36. MySQL database management software. [http://www.mysql.com]
  37. Heneweer C, Kruse LH, Kindhauser F, Schmidt M, Jakobs KH, Denker HW, Thie M: Adhesiveness of human uterine epithelial RL95-2 cells to trophoblast: rho protein regulation. Mol Hum Reprod. 2002, 8 (11): 1014-1022. 10.1093/molehr/8.11.1014.View ArticlePubMedGoogle Scholar
  38. Rahnama F, Thompson B, Steiner M, Shafiei F, Lobie PE, Mitchell MD: Epigenetic regulation of E-cadherin controls endometrial receptivity. Endocrinology. 2009, 150 (3): 1466-1472. 10.1210/en.2008-1142.View ArticlePubMedGoogle Scholar
  39. Kininis M, Kraus WL: A global view of transcriptional regulation by nuclear receptors: gene expression, factor localization, and DNA sequence analysis. Nucl Recept Signal. 2008, 6: e005-PubMed CentralPubMedGoogle Scholar
  40. Cowley SM, Hoare S, Mosselman S, Parker MG: Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem. 1997, 272 (32): 19858-19862. 10.1074/jbc.272.32.19858.View ArticlePubMedGoogle Scholar
  41. Lindberg MK, Moverare S, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson JA, Ohlsson C: Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a "ying yang" relationship between ERalpha and ERbeta in mice. Mol Endocrinol. 2003, 17 (2): 203-208. 10.1210/me.2002-0206.View ArticlePubMedGoogle Scholar
  42. Takamoto N, Zhao B, Tsai SY, DeMayo FJ: Identification of Indian hedgehog as a progesterone-responsive gene in the murine uterus. Mol Endocrinol. 2002, 16 (10): 2338-2348. 10.1210/me.2001-0154.View ArticlePubMedGoogle Scholar
  43. Khatua A, Wang X, Ding T, Zhang Q, Reese J, DeMayo FJ, Paria BC: Indian hedgehog, but not histidine decarboxylase or amphiregulin, is a progesterone-regulated uterine gene in hamsters. Endocrinology. 2006, 147 (9): 4079-4092. 10.1210/en.2006-0231.View ArticlePubMedGoogle Scholar
  44. Lee K, Jeong J, Kwak I, Yu CT, Lanske B, Soegiarto DW, Toftgard R, Tsai MJ, Tsai S, Lydon JP, et al: Indian hedgehog is a major mediator of progesterone signaling in the mouse uterus. Nat Genet. 2006, 38 (10): 1204-1209. 10.1038/ng1874.View ArticlePubMedGoogle Scholar
  45. Simon L, Spiewak KA, Ekman GC, Kim J, Lydon JP, Bagchi MK, Bagchi IC, DeMayo FJ, Cooke PS: Stromal progesterone receptors mediate induction of Indian Hedgehog (IHH) in uterine epithelium and its downstream targets in uterine stroma. Endocrinology. 2009, 150 (8): 3871-3876. 10.1210/en.2008-1691.PubMed CentralView ArticlePubMedGoogle Scholar
  46. Torchia J, Glass C, Rosenfeld MG: Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol. 1998, 10 (3): 373-383. 10.1016/S0955-0674(98)80014-8.View ArticlePubMedGoogle Scholar
  47. Khan OY, Nawaz Z: Nuclear hormone receptor co-regulators. Curr Opin Drug Discov Devel. 2003, 6 (5): 692-701.PubMedGoogle Scholar
  48. Ellmann S, Sticht H, Thiel F, Beckmann MW, Strick R, Strissel PL: Estrogen and progesterone receptors: from molecular structures to clinical targets. Cell Mol Life Sci. 2009, 66 (15): 2405-2426. 10.1007/s00018-009-0017-3.View ArticlePubMedGoogle Scholar
  49. Losel R, Wehling M: Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol. 2003, 4 (1): 46-56. 10.1038/nrm1009.View ArticlePubMedGoogle Scholar
  50. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, et al: Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001, 104 (5): 719-730.PubMedGoogle Scholar

Copyright

© Tamm et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement